Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Worldwide prevalence of emerging parasite Blastocystis in immunocompromised patients: A systematic review and meta-analysis

Wed Sep 28 07:04:18 2022

(2020) Worldwide prevalence of emerging parasite Blastocystis in immunocompromised patients: A systematic review and meta-analysis. Microbial pathogenesis. p. 104615. ISSN 1096-1208 (Electronic) 0882-4010 (Linking)

Full text not available from this repository.

Official URL: https://www.ncbi.nlm.nih.gov/pubmed/33246090

Abstract

BACKGROUND: Blastocystis is one of the most common pathogens of the human intestine, caused by an emerging parasite, which can lead to severe symptoms and even death in immunocompromised patients. We aimed to determine the global prevalence of Blastocystosis infection in people with immunodeficiency. A systematic literature search was conducted on Web of Science, Scopus, Google scholar, Science Direct and MEDLINE databases to select all observational studies reporting the prevalence of Blastocystosis infection in Worldwide, based on different diagnostic methods in immunocompromised patients of any age and published from inception to February 2019. Pooled estimates and 95 confidence intervals (95 CIs) were calculated using random effects models and in addition, the I(2) statistic was calculated. The geographic distribution of studies was evaluated and the diagnosis of Blastocystis was compared by various techniques. Electronic databases were reviewed for Blastocystosis infection in HIV/AIDS, cancer and other immunocompromised patients, and meta-analyses were conducted to calculate the overall estimated prevalence. Total68 eligible studies were included. The estimated pooled prevalence rate of Blastocystosis infection in immunocompromised patients was overall 10 (95 CI, 7-13; I(2) 96.04) (P < 0.001), of whom 21 18-25 were in Australia, 12% 4-24 in America, 11% 6-17 in Europe and 10% 5-15, 7% 3-13 in Asia and Africa, respectively. It was calculated that the estimated pooled prevalence rate of Blastocystosis infection in immunocompromised patients was overall 10% and the prevalence estimates ranged from 0.44 to 72.39. Also, overall the prevalence of parasites co-infection in immunocompromised patients was detected as 0.024%. Our finding showed that immunocompromised people show a high prevalence of Blastocystosis infection compared to the control population. Adequate information on the prevalence rate is still missing from many countries. However, current information underscore that Blastocystis should not be neglected.

Item Type: Article
Creators:
CreatorsEmail
Khorshidvand, Z.UNSPECIFIED
Khazaei, S.UNSPECIFIED
Amiri, M.UNSPECIFIED
Taherkhani, H.UNSPECIFIED
Mirzaei, A.UNSPECIFIED
Keywords: Blastocystis Blastocystosis infection Cancer patients HIV/AIDS patients Immunocompromised patients Prevalence
Divisions:
Page Range: p. 104615
Journal or Publication Title: Microbial pathogenesis
Journal Index: Pubmed
Identification Number: https://doi.org/10.1016/j.micpath.2020.104615
ISSN: 1096-1208 (Electronic) 0882-4010 (Linking)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/3239

Actions (login required)

View Item View Item